

**EUROPEAN  
CURRICULUM VITAE  
FORMAT**



**INFORMAZIONI PERSONALI**

Nome **BORGHETTI PAOLO**  
Indirizzo  
Telefono  
Fax  
E-mail  
  
Nazionalità Italiana  
Data di nascita 19/03/1982

**EDUCAZIONE E FORMAZIONE**

19/10/2007 Laurea in Medicina e Chirurgia  
Università degli Studio di Brescia – Facoltà di Medicina  
108/110  
Le conseguenze sulla sopravvivenza: incidenza a lungo termine di secondi tumori in una casistica retrospettiva di oltre 2000 casi di linfoma di Hodgkin trattati con radioterapia e chemioterapia

29/03/2012 Specializzazione in Radioterapia  
Università degli Studio di Brescia  
50/50 “cum laude”  
Radioterapia panencefalica con *boost* sequenziale o concomitante nelle metastasi cerebrali: confronto dosimetrico preliminare tra tecnica volumetrica ed elicale.

Maggio 2011- agosto 2011 Training  
Odense University – Oncology Department Medical School  
Has the quality of vessels a value in the treatment of Glioblastoma Multiforme? A study on the role of GLUT1 in neoangiogenesis

**ESPERIENZE LAVORATIVE**

MAGGIO 2012 - AGOSTO 2012 RADIOTERAPISTA c/o “AZIENDA SPEDALI CIVILI DI BRESCIA”  
MEDIPASS SRL – BOLOGNA

GENNAIO 2013 - AGOUST 2014 RADIOTERAPISTA c/o “AZIENDA SPEDALI CIVILI DI BRESCIA”  
MEDIPASS SRL – BOLOGNA

AGOSTO 2014 - OGGI RADIOTERAPISTA c/o “AZIENDA SPEDALI CIVILI DI BRESCIA”

## ABILITÀ PERSONALI E COMPETENZE

LINGUA MADRE  
ALTRE LINGUE

- letto
- scritto
- parlato

ITALIANO

INGLESE

BUONO

BUONO

BUONO

## PUBBLICAZIONI

Three- dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk. Michela Buglione, Luigi Spiazzi, Federica Saiani, Loredana Costa, Blerina Shehi, Barbara Lazzari, Chiara Uccelli, Nadia Pasinetti, Paolo Borghetti, Luca Triggiani, Laura Donadoni, Sara Pedretti, and Stefano M Magrini, on behalf of the Neuro-Oncology Group, Spedali Civili, Brescia University, Brescia, Italy  
Tumori, 2014, 100: 272-277

A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian Centres from 1977 to 2000. Part II: evolving technical choices and toxicity patterns. Magrini SM, Tonoli S, Costa L, Pasinetti N, Paiar F, Livi L, Simontacchi G, Meattini I, Pegurri L, Borghetti P, Frata P, Ponticelli P, Buglione M, Biti G.  
Radiol Med. 2012 Jun; 117 (4): 715-24.

The impact of tumour histology and recursive partitioning analysis classification on the prognosis of patients treated with whole-brain hypofractionated radiotherapy for brain metastases: analysis of 382 patients. Buglione M, Bandera L, Grisanti S, Pasinetti N, Borghetti P, Barbera F, Triggiani L, Costa L, Shehi B, Bonetti B, Magrini S.  
Radiol Med. 2012 Feb;117(1):133-47.

Transdermal buprenorphine for oropharyngeal mucositis-associated pain in patients treated with radiotherapy for head and neck cancer. Huscher A, De Stefani A, Smussi I, Borghetti P, Pasinetti N, Bonetti B, Magrini SM. J Palliat Med. 2010 Apr;13(4):357-8

## SEMINARI E CONGRESSI

Brescia meetings in radiation oncology: "Radiobiology: from a morphologic to a functional approach and from bench to bedside", University of Brescia, Brescia (Italy), May 9<sup>th</sup>, 2008

5th Conference on "Integrated therapies in oncology - state of art and future challenges..." University of Messina, Messina (Italy), July 8<sup>th</sup> -10<sup>th</sup> , 2008

Brescia meetings in radiation oncology: "Biology and technology contribution to clinical advancement: the case of oropharyngeal cancer", University of Brescia (Italy), Brescia, May 8<sup>th</sup>, 2009

XVIII National Congress AIRO (Italian Association of Radiation Oncology), Milan (Italy) November 15<sup>th</sup> -18<sup>th</sup> , 2008

ESTRO teaching course on Evidence based radiation oncology: Methodological Basis and clinical application, ESTRO, Wien (Austria) September 5<sup>th</sup> – 10<sup>th</sup> , 2009

XIX National Congress AIRO (Italian Association of Radiation Oncology), Bologna (Italy) November 14<sup>th</sup> -17<sup>th</sup>, 2009

20° Residential update course "Modern Radiotherapy, New Standards And Therapeutic Effectiveness Of Care Measure", Catholic University "Sacro Cuore", Roma (Italy) March 15<sup>th</sup> - 19<sup>th</sup> , 2010

The oncologist meets the pathologist: The Genitourinary, Accademia nazionale di Medicina, Arezzo (Italy), April 30<sup>th</sup>, 2010

The management of patients with cancer urogenital from clinical practice to doctor-patient communication, Bertinoro (FC) (Italy), May 6<sup>th</sup> -8<sup>th</sup> , 2010

Brescia meetings in radiation oncology: "Hodgkin and Non Hodgkin Lymphomas: a new role for radiation therapy", University of Brescia (Italy), Brescia (Italy), May 14<sup>th</sup> 2010

Corso di aggiornamento "Appropriatezza in Radioterapia "; Naples, (Italy) June 14<sup>th</sup> -16<sup>th</sup> , 2010

Secondo incontro nazionale di aggiornamento – Gruppo di lavoro Neoplasie cerebrali AIRO – Roma, September 13<sup>th</sup>, 2010

ESTRO 29 Congress, Barcelona (Spain) September 12<sup>th</sup> -16<sup>th</sup> , 2010

XX National Congress AIRO (Italian Association of Radiation Oncology), Naples (Italy) November 13<sup>th</sup> -16<sup>th</sup> ,2010

EORTC-EANO Conference 2011 Trends in Central Nervous System Malignancies, Bucharest (Romania); March 25<sup>th</sup> – 26<sup>th</sup>, 2011

Brescia meetings in radiation oncology: "Breast Cancer: Toward a patient-centred perspective", University of Brescia (Italy), Brescia (Italy), September 30<sup>th</sup>, 2011

3<sup>rd</sup> European Multidisciplinary meeting on Urological Cancers (EMUC 2011), Barcelona (Spain) November 4<sup>th</sup> - 6<sup>th</sup> , 2011

ICTR-PHE 2012 International Conference on Translational Research in Radio-Oncology and Physics for Health in Europe, Geneve (Swiss), February 27<sup>th</sup> – March 2<sup>nd</sup> , 2012 (Speaker)

Clinical Practice & Implementation of Image-Guided Stereotactic body Radiotherapy (ESTR Teaching Course, Wurzburg (Germany) , September 2<sup>nd</sup>-6<sup>th</sup>, 2012

XXII National Congress AIRO (Italian Association of Radiation Oncology), Rome (Italy) November 17<sup>th</sup> -20<sup>th</sup> ,2012

Nuove terapie, percorsi diagnostici ed impatto sulla qualità della vita del paziente affetto da NSCLC, Brescia (Italy), March 22<sup>nd</sup>, 2013

Difficult Climbing: treatment of gliomas and a tribute to prof. g.B. Biti, Brescia (Italy), October, 3<sup>rd</sup> -4<sup>th</sup>, 2013

Approccio multidisciplinare al carcinoma polmonare: trattamento delle metastasi del NSCLC – Aggiornamenti 2013, Brescia (Italy), December 6<sup>th</sup>, 2013 (Speaker)

## ALTRI INTERESSI PROFESSIONALI

He is involved in the clinical management of patient included in clinical randomized perspective national and international trials:

Phase III randomized study of early fludeoxglucose<sup>18</sup> positron emission tomography scan-guided treatment adaptation versus standard combined modality treatment in patients with previously untreated supradiaphragmatic stage I or II Hodgkin's lymphoma

Cilengitide, Temozolomide, and radiation therapy in treating patients with newly diagnosed Glioblastoma and methylated gene promoter status (centric)

Randomized prospective phase II trial in patients with RPA prognostic class V and VI Glioblastoma: comparison between hypofractionated radiotherapy (RT) 30 Gy (6 fractions in two weeks) and Temozolomide (TMZ) exclusive (200 mg / sqm / day for 5 days every 28 days)

SIB-GBM (simultaneous integrated boost Glioblastoma multiforme) trial: hypofractionated with concomitant boost radiotherapy and in combination with Temozolomide in RPA class III and IV Glioblastoma patients. Prospective phase II - multicenter protocol.

He is involved in the clinical interpretation and statistical analysis of the results from a retrospectively collected series of patients treated at radiotherapy department, Brescia university for Hodgkin lymphoma, prostate cancer, CNS tumors and breast cancer

He is involved in the national scientific program funded in 2007 by the national university ministry titled: "response evaluation in locally advanced head and neck cancers with circulating tumor cells, biological markers and modern functional imaging"

He is dealing with the implementation of stereotactic body radiotherapy